(AP Photo/Manuel Balce Ceneta, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] WASHINGTON (AP) — ...

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Please provide your email address to receive an email when new articles are posted on . Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints.

WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.